Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Analysis of Clinical data

Salivary glands

Fig 1. Function loss for the parotid glands below and above specified dose thresholds (a) and calculated dose response curves for IMRT-treatments (b).
© dkfz.de

For radiotherapy treatments of head-and-neck tumors, the salivary glands are often within the treatment fields and may receive high doses. Xerostomia may be the consequence, which severely affects life quality of patients. Using intensity-modulated radiotherapy (IMRT) the degree of dose conformation to the tumor can be improved and the dose to at least one parotid gland can be significantly reduced.
To assess the preservation of salivary gland function, functional parameters are measured using quantitative pertechnetate scintigraphy. The change of these parameters before and after radiotherapy are analyzed as a a function of dose and dose response relations are derived (fig. 1). In addition, the functional changes between different treatment modalities are compared. These treatment modalities include conventional radiotherapy with and without administration of the radio-protector Amifostine and IMRT.

Lung

Radiological changes in computed tomography (CT) after radiotherapy of lung tumors are regarded as a leading sign for radiological fibrosis, which subsequently may lead to clinical pneumonitis. In such cases, loss of lung function may be the consequence. To avoid such complication, the irradiated volume of the lung should be kept as small as possible. For selected lung tumors, the irradiated volume may be minimized by rigid immobilization of the patient and by applying a high single dose (stereotactic Radiosurgery).
For a collective of patient with lung tumors treated, the probability of radiological changes in CT after stereotactic radiosurgery is investigated and dose response curves are derived. In addition, the clinical response is analyzed as a function of the irradiated volume and the location of the tumor. Quantitative predictive parameters shell be derived to allow the estimation of complication probabilities in radiosurgery of the lung already at the stage of treatment planning.

Cooperations

  • Dr. M. Münter, Dr. H. Hof, Dept. of Radiation Oncology and Radiotherapy, University Clinic Heidelberg, Germany

Selected References

  • Münter M.W., Karger C.P., Hoffner S.G., Hof H., Thilmann C., Rudat V., Nill S., Wannenmacher M., Debus J.; Evaluation of salivary gland function after treatment of head-and-neck tumors with intensity-modulated radiotherapy by quantitative pertechnetate scintigraphy. International Journal of Radiation Oncology, Biology, Physics 58, 175-184, 2004
  • Hof H., Herfarth K.K., Munter M., Hoess A., Motsch J., Wannenmacher M., Debus J.: Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int. J. Radiat. Oncol. Biol. Phys. 56, 335-341, 2003

to top
powered by webEdition CMS